MeiraGTx Holdings plc (MGTX) stock
MGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/3065% below fair value
$7.98−0.16 (-1.97%)
Close on Nov 20, 2026Market cap $766.42MP/E 11.2Yield –
MeiraGTx shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
MeiraGTx's shares outstanding was 94M at Jun 30, 2026. For fiscal 2025 it was 80M, up 15.2% from the year before. The highest annual figure on record is 80M in fiscal 2025.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 80M | +15.2% |
| FY2024 | Dec 31, 2024 | 70M | +23.6% |
| FY2023 | Dec 31, 2023 | 56M | +25.0% |
| FY2022 | Dec 31, 2022 | 45M | +2.4% |
| FY2021 | Dec 31, 2021 | 44M | +17.0% |
| FY2020 | Dec 31, 2020 | 38M | +13.8% |
| FY2019 | Dec 31, 2019 | 33M | +75.0% |
| FY2018 | Dec 31, 2018 | 19M | +121.0% |
| FY2017 | Dec 31, 2017 | 9M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 94M | +16.4% |
| Q1 FY2026 | Mar 31, 2026 | 81M | +2.9% |
| Q4 FY2025 | Dec 31, 2025 | 81M | +2.5% |
| Q3 FY2025 | Sep 30, 2025 | 81M | +13.0% |
| Q2 FY2025 | Jun 30, 2025 | 81M | +25.2% |
| Q1 FY2025 | Mar 31, 2025 | 79M | +23.4% |
| Q4 FY2024 | Dec 31, 2024 | 79M | +27.0% |
| Q3 FY2024 | Sep 30, 2024 | 72M | +20.3% |
| Q2 FY2024 | Jun 30, 2024 | 64M | +16.3% |
| Q1 FY2024 | Mar 31, 2024 | 64M | +31.7% |
| Q4 FY2023 | Dec 31, 2023 | 62M | +33.0% |
| Q3 FY2023 | Sep 30, 2023 | 60M | +33.2% |
| Q2 FY2023 | Jun 30, 2023 | 55M | +23.9% |
| Q1 FY2023 | Mar 31, 2023 | 49M | +9.3% |
| Q4 FY2022 | Dec 31, 2022 | 47M | +5.8% |
| Q3 FY2022 | Sep 30, 2022 | 45M | +1.2% |
| Q2 FY2022 | Jun 30, 2022 | 45M | +1.2% |
| Q1 FY2022 | Mar 31, 2022 | 45M | +1.2% |
| Q4 FY2021 | Dec 31, 2021 | 44M | +10.5% |
| Q3 FY2021 | Sep 30, 2021 | 44M | +18.7% |
| Q2 FY2021 | Jun 30, 2021 | 44M | +19.4% |
| Q1 FY2021 | Mar 31, 2021 | 44M | +20.1% |
| Q4 FY2020 | Dec 31, 2020 | 40M | +10.4% |
| Q3 FY2020 | Sep 30, 2020 | 37M | +7.4% |
| Q2 FY2020 | Jun 30, 2020 | 37M | +12.6% |
| Q1 FY2020 | Mar 31, 2020 | 37M | +27.3% |
| Q4 FY2019 | Dec 31, 2019 | 36M | +35.9% |
| Q3 FY2019 | Sep 30, 2019 | 35M | +31.6% |
| Q2 FY2019 | Jun 30, 2019 | 33M | +141.2% |
| Q1 FY2019 | Mar 31, 2019 | 29M | +222.3% |
| Q4 FY2018 | Dec 31, 2018 | 27M | +207.9% |
| Q3 FY2018 | Sep 30, 2018 | 26M | +206.0% |
| Q2 FY2018 | Jun 30, 2018 | 14M | +60.0% |
| Q1 FY2018 | Mar 31, 2018 | 9M | – |
| Q4 FY2017 | Dec 31, 2017 | 9M | – |
| Q3 FY2017 | Sep 30, 2017 | 9M | – |
| Q2 FY2017 | Jun 30, 2017 | 9M | – |
See a number that looks wrong?